Neurology · Opioid Use DisorderTrial Updateclinicalmid-term

Pilot Study on Deep Brain Stimulation for Opioid Use Disorder Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:30:32 PM

Assessment confidence: 92% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The initiation of a pilot study on deep brain stimulation for opioid use disorder represents a potential shift in treatment paradigms for a challenging condition. Success in this trial could lead to new therapeutic options, impacting existing addiction therapies and strategies for companies in this space. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

Strategic Assessment

If successful, this could lead to new treatment options, influencing portfolio strategies for companies involved in addiction therapies. The strongest clinical anchor is Deep Brain Stimulation Effects In Patients With Opioid Use Disorder (ClinicalTrials.gov), sub-indication match (pain); entity match (abbott). In pain, 1 regulatory and 0 competitive items passed relevance filtering for Abbott.

Competitive Pressure

The most relevant competitive pressure comes from This study could provide insights into novel treatment approaches for opioid use disorder, potentially impacting existing therapies and competitors in addiction treatment..

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). Successful outcomes may lead to further clinical trials and eventual regulatory submissions, influencing the approval landscape for new treatment modalities in opioid use disorder.

Key Risks

Elevated medium regulatory exposure for Abbott could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the pilot study demonstrates efficacy, it could open new revenue streams for companies involved in addiction treatment, potentially altering market share dynamics.
If successful, this could lead to new treatment options, influencing portfolio strategies for companies involved in addiction therapies.

What Would Change This Assessment

This becomes more urgent if Monitor results from this pilot study and any subsequent trials that may expand on these findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source

Deep Brain Stimulation Effects In Patients With Opioid Use Disorder
ClinicalTrials.govhigh relevance
Sub-indication match (pain); Entity match (abbott)
FDA document
View source
VIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Promoting Recovery After Brain Injury Using Focused Ultrasound
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Abbott

Commercial impact

medium

If the pilot study demonstrates efficacy, it could open new revenue streams for companies involved in addiction treatment, potentially altering market share dynamics.

Regulatory impact